You are currently viewing a beta version of our website. If you spot anything unusual, kindly let us know.
Altmetrics
Downloads
129
Views
49
Comments
0
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
The name of the study | The year of the Study | The Phase of the Study | Research Group | Dose of Bevacizumab | Results |
---|---|---|---|---|---|
GOG-0218 [54] | 2011 | Phase III | 1873 patients with ovarian cancer with newly diagnosed stage III (incompletely resectable) or stage IV epithelial ovarian cancer who had undergone debulking surgery to receive one of three treatments | Bevacizumab-initiation: chemotherapy + bevacizumab (15 mg/kg), cycles 2-6, placebo, cycles 7-22. Bevacizumab-throughout: chemotherapy + bevacizumab, cycles: 2-22. | Median PFS: control 10.3 months bevacizumab-initiation group: 11.2, bevacizumab-throughout group 14.1. |
ICON-7 [56] | 2015 | Phase III | 1528 patients with newly diagnosed ovarian cancer | Bevacizumab 7.5 mg/kg every 3 weeks, given concurrently and continued with up to 12 further 3-weekly cycles of maintenance therapy. |
The mean PFS: chemotherapy + bevacizumab: 36.3 months, standard chemotherapy: 34.5 months. Median OS: chemotherapy + bevacizumab: 45.4 months, standard chemotherapy: 44.6 months. |
PAOLA-1 [57] | 2023 | Phase III | 809 patients with ovarian cancer | Olaparib (300 mg twice daily for up to 24 months) + bevacizumab (15 mg/kg every 3 weeks for 15 months); placebo group: bevacizumab alone |
Median OS: olaparib + bevacizumab: 56.5 months, bevacizumab grouo: 51.6 months 5-year OS in patients with HRD-positive ovarian cancer (65.5%) compared to patients with HRD-negative ovarian cancer (48.4%) |
AGO-OVAR 17 BOOS/GINECO OV118/ENGOT Ov-15 [58] | 2023 | Phase III | 927 patients with newly diagnosed stage IIB-IV ovarian cancer | Bevacizumab at a dose of 15 mg/kg once every 3 weeks for 15 or 30 months. | The median PFS: standard duration of bevacizumab: 24.2 months, extended duration of bevacizumab: 26.0 months. No difference was found between patient groups in the median OS. |
Gilbert et al. [59] | 2023 | Phase Ib/II | 94 Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose most recent platinum-free interval was ≤6 months | Mirvetuximab soravtansine (6 mg/kg adjusted ideal body weight) and bevacizumab (15 mg/kg), intravenously, once every 3 weeks |
The median PFS was 8.2 months and the median DOR was 9.7 months |
The name of the Study | The year of the Study | The Phase of the Study | Research Group | Dose of Bevacizumab | Results |
---|---|---|---|---|---|
GOG 227C [72] | 2009 | Phase II trial | 46 patients with advanced cervical cancer, (82.6%) 38 of them received prior radiation as well as either one (n=34) or two (n=12) prior cytotoxic regimens for recurrent disease. | Bevacizumab: 15 mg/kg every 3 weeks until disease progression or prohibitive toxicity | PFS was 3.4 months and OS - 7.3 months |
GOG 240 [73] | 2014 | Phase III trial | 452 patients with advanced cervical cancer to chemotherapy with (n=227) or without (n=225) bevacizumab | Bevacizumab: 15 mg/kg | Bevacizumab together with the chemotherapy in patients with metastatic, recurrent or persistent cervical cancer improved the OS, which was 3.7 months higher than in a group without bevacizumab. |
Gynecologic Oncology Group 240 [74] | 2017 | Phase III trial | 452 patients with advanced cervical cancer | Bevacizumab administered intravenously at a dose of 15 mg/kg on day 1 in 21-day cycles. | Efficacy and tolerability of bevacizumab in the treatment of a advanced cervical cancer. |
Authors of the study | The year of the Study | The phase of the Study | Research Group | Dose of Bevacizumab | Results |
---|---|---|---|---|---|
Wright et al. [79] | 2007 | A retrospective analysis | 11 patients, including 9 patients with epithelial endometrial carcinomas and 2 with leiomyosarcomas. | Median cumulative dose received by patients was 4.679 mg. | Median PFS was 5.4 months for the entire cohort and 8.7 months for those who achieved clinical benefit, bevacizumab was well tolerated. |
Aghajanian et al. [80] | 2011 | Phase II | 56 patients, 29 had received prior radiation. | Treatment consisted of bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression or prohibitive toxicity. | Median PFS and OS were 4.2 and 10.5 months, bevacizumab was well tolerated in recurrent or persistent endometrial cancer. |
Alvarez et al. [81] | 2012 | Phase II | 53 patients, 20 had received prior radiation. | Bevacizumab 10 mg/kg every other week. | PFS and OS were 5.6 and 16.9 months, respectively. |
Rubinstein et al. [82] | 2021 | A retrospective analysis | 101 patients including 13 grade 1/2 endometrioid, 15 grade 3 endometrioid, 44 serous, 8 carcinosarcoma, and 21 other/mixed histologies. | 85 patients started bevacizumab at a dose of 15 mg/kg, 9 started at 10 mg/kg, and 7 started at 7.5 mg/kg, with dosing every 3 weeks. | Median PFS ranged from 2.6 months (2 lines) to 4.9 months (≥4 lines), the median OS was 3.4 years. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
Submitted:
18 February 2024
Posted:
19 February 2024
You are already at the latest version
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
Submitted:
18 February 2024
Posted:
19 February 2024
You are already at the latest version
The name of the study | The year of the Study | The Phase of the Study | Research Group | Dose of Bevacizumab | Results |
---|---|---|---|---|---|
GOG-0218 [54] | 2011 | Phase III | 1873 patients with ovarian cancer with newly diagnosed stage III (incompletely resectable) or stage IV epithelial ovarian cancer who had undergone debulking surgery to receive one of three treatments | Bevacizumab-initiation: chemotherapy + bevacizumab (15 mg/kg), cycles 2-6, placebo, cycles 7-22. Bevacizumab-throughout: chemotherapy + bevacizumab, cycles: 2-22. | Median PFS: control 10.3 months bevacizumab-initiation group: 11.2, bevacizumab-throughout group 14.1. |
ICON-7 [56] | 2015 | Phase III | 1528 patients with newly diagnosed ovarian cancer | Bevacizumab 7.5 mg/kg every 3 weeks, given concurrently and continued with up to 12 further 3-weekly cycles of maintenance therapy. |
The mean PFS: chemotherapy + bevacizumab: 36.3 months, standard chemotherapy: 34.5 months. Median OS: chemotherapy + bevacizumab: 45.4 months, standard chemotherapy: 44.6 months. |
PAOLA-1 [57] | 2023 | Phase III | 809 patients with ovarian cancer | Olaparib (300 mg twice daily for up to 24 months) + bevacizumab (15 mg/kg every 3 weeks for 15 months); placebo group: bevacizumab alone |
Median OS: olaparib + bevacizumab: 56.5 months, bevacizumab grouo: 51.6 months 5-year OS in patients with HRD-positive ovarian cancer (65.5%) compared to patients with HRD-negative ovarian cancer (48.4%) |
AGO-OVAR 17 BOOS/GINECO OV118/ENGOT Ov-15 [58] | 2023 | Phase III | 927 patients with newly diagnosed stage IIB-IV ovarian cancer | Bevacizumab at a dose of 15 mg/kg once every 3 weeks for 15 or 30 months. | The median PFS: standard duration of bevacizumab: 24.2 months, extended duration of bevacizumab: 26.0 months. No difference was found between patient groups in the median OS. |
Gilbert et al. [59] | 2023 | Phase Ib/II | 94 Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose most recent platinum-free interval was ≤6 months | Mirvetuximab soravtansine (6 mg/kg adjusted ideal body weight) and bevacizumab (15 mg/kg), intravenously, once every 3 weeks |
The median PFS was 8.2 months and the median DOR was 9.7 months |
The name of the Study | The year of the Study | The Phase of the Study | Research Group | Dose of Bevacizumab | Results |
---|---|---|---|---|---|
GOG 227C [72] | 2009 | Phase II trial | 46 patients with advanced cervical cancer, (82.6%) 38 of them received prior radiation as well as either one (n=34) or two (n=12) prior cytotoxic regimens for recurrent disease. | Bevacizumab: 15 mg/kg every 3 weeks until disease progression or prohibitive toxicity | PFS was 3.4 months and OS - 7.3 months |
GOG 240 [73] | 2014 | Phase III trial | 452 patients with advanced cervical cancer to chemotherapy with (n=227) or without (n=225) bevacizumab | Bevacizumab: 15 mg/kg | Bevacizumab together with the chemotherapy in patients with metastatic, recurrent or persistent cervical cancer improved the OS, which was 3.7 months higher than in a group without bevacizumab. |
Gynecologic Oncology Group 240 [74] | 2017 | Phase III trial | 452 patients with advanced cervical cancer | Bevacizumab administered intravenously at a dose of 15 mg/kg on day 1 in 21-day cycles. | Efficacy and tolerability of bevacizumab in the treatment of a advanced cervical cancer. |
Authors of the study | The year of the Study | The phase of the Study | Research Group | Dose of Bevacizumab | Results |
---|---|---|---|---|---|
Wright et al. [79] | 2007 | A retrospective analysis | 11 patients, including 9 patients with epithelial endometrial carcinomas and 2 with leiomyosarcomas. | Median cumulative dose received by patients was 4.679 mg. | Median PFS was 5.4 months for the entire cohort and 8.7 months for those who achieved clinical benefit, bevacizumab was well tolerated. |
Aghajanian et al. [80] | 2011 | Phase II | 56 patients, 29 had received prior radiation. | Treatment consisted of bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression or prohibitive toxicity. | Median PFS and OS were 4.2 and 10.5 months, bevacizumab was well tolerated in recurrent or persistent endometrial cancer. |
Alvarez et al. [81] | 2012 | Phase II | 53 patients, 20 had received prior radiation. | Bevacizumab 10 mg/kg every other week. | PFS and OS were 5.6 and 16.9 months, respectively. |
Rubinstein et al. [82] | 2021 | A retrospective analysis | 101 patients including 13 grade 1/2 endometrioid, 15 grade 3 endometrioid, 44 serous, 8 carcinosarcoma, and 21 other/mixed histologies. | 85 patients started bevacizumab at a dose of 15 mg/kg, 9 started at 10 mg/kg, and 7 started at 7.5 mg/kg, with dosing every 3 weeks. | Median PFS ranged from 2.6 months (2 lines) to 4.9 months (≥4 lines), the median OS was 3.4 years. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
Daniela Califano
et al.
Cancers,
2021
Dharma Khatiwada
et al.
Mathematics,
2023
Michael Toboni
et al.
Cancers,
2021
© 2024 MDPI (Basel, Switzerland) unless otherwise stated